All In Biotech

Drug Trial Radar · NCT07227207

A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)

A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated With Severe Alpha-1 Antitrypsin Deficiency

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Apr 21, 2026

Primary completion

Mar 2029

Study completion Mar 2029

Sponsor

Lead sponsor
Tessera Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver disease associated with severe alpha-1 antitrypsin deficiency (AATD)

Conditions

  • Alpha-1 Antitrypsin Deficiency (AATD)

Interventions

  • TSRA-196Drug

    TSRA-196 is an in-vivo genome editing product formulated in lipid nanoparticles (LNPs) for the treatment of patients with alpha-1 antitrypsin deficiency (AATD), via intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (Dose Escalation): Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: 1 Year
  2. Part 2 (Dose Expansion): Proportion of participants who have serum levels of total alpha-1 antitrypsin (AAT) greater than or equal to Lower Limit of Normal (LLN) after TSRA-196 treatmentTime frame: 1 Year
  3. Part 2 (Dose Expansion): Change in functional AAT concentrations (determined using an elastase inhibition assay) from baseline to end of studyTime frame: 1 Year
  4. Part 3 (Single Repeated Dose): Proportion of participants who have serum levels of total alpha-1 antitrypsin (AAT) greater than or equal to Lower Limit of Normal (LLN) after a second dose of TSRA-196Time frame: 1 Year

Locations

10 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Study Center

    Jacksonville, Florida · Recruiting

  • Clinical Study Center

    Boston, Massachusetts · Recruiting

  • Clinical Study Center

    Rochester, Minnesota · Recruiting

  • Clinical Study Center

    Charleston, South Carolina · Recruiting

  • Clinical Study Center

    Seattle, Washington · Recruiting

  • Clinical Study Center

    Fitzroy, Victoria, Australia · Recruiting

  • Clinical Study Center

    Leiden, Netherlands · Recruiting

  • Clinical Study Center

    Gothenburg, Sweden · Recruiting

  • Clinical Study Center

    London, United Kingdom · Recruiting

  • Clinical Study Center

    Nottingham, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.